Antihypertensive effect of verapamil in patients with newly discovered mild to moderate essential hypertension.
The antihypertensive effect of verapamil (Isoptin) 120 mg X 3 for four weeks was compared with that of placebo in a randomized, double-blind, cross-over investigation. Twenty patients with newly discovered, not previously treated, mild to moderate essential hypertension were included in the study. Verapamil significantly reduced the diastolic and systolic blood pressure in the supine and standing positions, as well as the heart rate. One patient discontinued the treatment because of rash. Otherwise, only constipation was registered as a side effect of Isoptin. No orthostatic reactions were observed and the PQ-interval was unchanged. Compliance was excellent.
D000328:Adult; D000368:Aged; D003248:Constipation / Q000139:chemically induced; D003971:Diastole / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013599:Systole / Q000187:drug effects; D013997:Time Factors; D014700:Verapamil / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D010919:Placebos; D014700:Verapamil